- Stocks
- Pharma & Healthcare
- Tejnaksh
Tejnaksh share price
NSE: TEJNAKSHPharma & HealthcareMedical Care Facilities
Tejnaksh at a glance
With a market capitalisation of ₹29 Cr, it ranks 3400th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 4.5% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3 Cr (−20.6% year on year) and net profit ₹0 Cr (−16.7%), on a consolidated basis. Promoters held 73.83% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹29 CrRank 3400 on NSE
- Price to book
- 0.89×FY26
- EPS (TTM)
- ₹0.58to Q4 FY26
- ROE
- 4.5%FY26
- ROCE
- 5.9%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 10.9%FY26
- Book value / share
- ₹13.36FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Tejnaksh quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Revenue YoY | +3.0% | +9.1% | +1.6% | +9.9% | −15.4% | −11.6% | −17.9% | −20.6% |
| Net profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | +275.0% | +6.6% | +3.7% | −8.7% | −65.0% | −49.2% | −48.2% | −16.7% |
| Net margin | 19.2% | 19.3% | 17.6% | 13.1% | 8.0% | 11.1% | 11.1% | 13.7% |
| EPS | ₹0.29 | ₹0.31 | ₹0.38 | ₹0.21 | ₹0.12 | ₹0.15 | ₹0.14 | ₹0.17 |
Tejnaksh financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | — |
| Operating profit | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | — |
| Net profit | ₹2 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | — |
| EPS (₹) | ₹1.97 | ₹2.48 | ₹1.36 | ₹0.89 | ₹1.29 | — |
| Total debt | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr | ₹1 Cr | ₹0 Cr |
| Shareholders' equity | ₹17 Cr | ₹20 Cr | ₹22 Cr | ₹24 Cr | ₹26 Cr | ₹27 Cr |
Tejnaksh shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.83% | 73.83% | 73.83% | 73.83% | 73.83% | 73.83% |
| Non-institutions | 26.17% | 26.17% | 26.17% | 26.17% | 26.17% | 26.17% |
Tejnaksh vs peers
The listed Pharma & Healthcare companies nearest to Tejnaksh by market capitalisation.
Ask anything about Tejnaksh
Pivot answers on the live chart with evidence you can check, and tests strategies against TEJNAKSH's own history. Try: “Why has TEJNAKSH moved over the last three months?” · “Backtest a 50-day moving-average crossover on TEJNAKSH over five years” · “Compare TEJNAKSH with MEDICAPQ on margins and valuation”
Frequently asked questions about Tejnaksh
What is the market cap of Tejnaksh?
Tejnaksh's market capitalisation is ₹29 Cr (₹29 Cr) at the 22 Oct 2026 close, ranking 3400th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Tejnaksh?
Return on equity was 4.5% in FY26 and return on capital employed was 5.9% in FY26 (consolidated figures).
Is Tejnaksh a debt-free company?
Tejnaksh is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Tejnaksh's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Tejnaksh reported revenue of ₹3 Cr, −20.6% year on year, and net profit of ₹0 Cr, −16.7% year on year.
What is the shareholding pattern of Tejnaksh?
As of 30 Jun 2026: promoters 73.83%, non-institutions 26.17%.
Who are Tejnaksh's competitors?
The listed Pharma & Healthcare companies closest to Tejnaksh by market cap are Medi-Caps, KK Shah Hospita, Panjon, Soni Medicare, Chennai Meenaks and SAMSRITA LABS.
Is Tejnaksh a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Tejnaksh's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TEJNAKSH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text